The Management led by Eric Goupil gathers a consortium to acquire Unither Pharmaceuticals from Ardian
Summary
The management team is significantly reinvesting its proceeds and the Company will continue to operate under Eric Goupils leadership as he transitions to the newly created role of Executive Chairman.Financial details of the transaction are not being disclosed.Eric Goupil, Executive Chairman at Unither Pharmaceuticals, said: With Ardians support, we have been able to strengthen our business in the US, expand into China and continue investing significantly to cope with our customers strong demand and fuel our future organic growth. Unither is a clear market leader in the BFS business space with its innovative and diversified product portfolio, a steady customer base and highly resilient revenue model. We are confident in Unithers long-term growth potential as the global CDMO market continues to benefit from an increase in pharma drug production and outsourcing trends. By reinvesting in Unither, we remain committed to supporting the management team in helping them execute on their continued growth strategy, both organically in the rapidly expanding BFS market and through selective strategic acquisitions. We are convinced that this new chapter to be written alongside GIC, IK and Keensight will enable the group to continue and accelerate its development, particularly internationally.Completion of the transaction is subject to relevant legal and regulatory approvals.